Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TTR | P02766 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | CCNC | P24863 | 3/20 | 0.47 |
| ▸ | CDK8 | P49336 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2383627 | 0.82 | CYP3A4 (0.60) | KMT2AKDM4ESMN1; SMN2TTRDPP4 | |
| SCHEMBL3153965 | 0.82 | CYP3A4 (0.60) | KMT2AKDM4ESMN1; SMN2TTRDPP4 | |
| SCHEMBL372011 | 0.82 | KDM4E (0.76) | KMT2AKDM4ESMN1; SMN2TTRDPP4 | |
| SCHEMBL372012 | 0.82 | KDM4E (0.76) | KMT2AKDM4ESMN1; SMN2TTRDPP4 | |
| SCHEMBL30634288 | 0.81 | CYP3A4 (0.50) | KMT2AKDM4ESMN1; SMN2TTRDPP4 | |
| SCHEMBL30634283 | 0.81 | CYP3A4 (0.47) | KMT2AKDM4ESMN1; SMN2TTRDPP4 | |
| SCHEMBL26790647 | 0.81 | FDPS (0.57) | KMT2AKDM4ETTRDPP4CYP3A4 | |
| SCHEMBL30634271 | 0.81 | FDPS (0.57) | KMT2AKDM4ETTRDPP4CYP3A4 | |
| SCHEMBL20153731 | 0.80 | TTR (0.49) | KMT2AKDM4ESMN1; SMN2TTRDPP4 | |
| SCHEMBL6537895 | 0.80 | KDM4E (0.49) | KMT2AKDM4ESMN1; SMN2TTRDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538519-B1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-28 | — | — | EP | disclosed |
| US-11028071-B2 | Indazole derivatives as alpha v integrin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200339540-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-29 | — | — | US | disclosed |
| US-10745384-B2 | Indazole derivatives as αv integrin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190256496-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
| WO-2018089357-A1 | INDAZOLE DERIVATIVES AS αV INTEGRIN ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339540-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | ITGAV, ITGB1, ITGB3 | KMT2A 4218/4885KDM4E 2806/4885SMN1; SMN2 3667/4885 |
| US-20190256496-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | ITGAV, ITGB1, ITGB3 | KMT2A 4218/4885KDM4E 2806/4885SMN1; SMN2 3667/4885 |
| US-10745384-B2 | Indazole derivatives as αv integrin antagonists | ITGB3, ITGB1, ITGAV | KMT2A 4169/4885KDM4E 3102/4885SMN1; SMN2 3792/4885 |
| US-11028071-B2 | Indazole derivatives as alpha v integrin antagonists | ITGAV, ITGB1, ITGB3 | KMT2A 4218/4885KDM4E 2806/4885SMN1; SMN2 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.